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Results: Cox regression demonstrated that men with self-reported sleep disturbances had a higher
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reported sleep disturbances (both P , .05). Binary logistic regression showed the increased risk
for both dementia (1114%) and AD (1192%) were highest when sleep disturbance was reported
at age 70 years (both P , .001). No group differences were found in Ab levels.
Conclusion: Improving sleep quality may help reduce the neurodegenerative risk in older men.
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Experimental studies in both animals and humans have
demonstrated that insufficient sleep exerts considerable
effects on brain health. When awake, there is a normal
accumulation of toxic substances in the brain of mice. Us-
ing convective flow between the cerebrospinal fluid and
interstitial fluid, these toxic metabolites are removed
from the murine brain during subsequent sleep, thereby
ensuring that the neuronal exposure to neurodegenerative
factors is kept at a minimum [1]. Of note, clearance dur-
ing sleep was as much as twofold faster than durings: The authors have nothing to disclose.
thor. Tel.: 146-18-471 4136; Fax: 146-18-511540.
ristian.benedict@neuro.uu.se
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/3.0/).
16/j.jalz.2014.08.104waking hours in this study [1], indicating that a normal
night’s sleep may be critical for maintaining brain health
in mice, and, most likely, also in humans. In line with
these findings, we have recently demonstrated in healthy
young men [2] that one night of total sleep deprivation in-
creases morning blood concentrations of neuron-specific
enolase (NSE)—an enzyme found in all neurons [3]—
and S100 calcium binding protein B (S-100B)—a protein
which is mainly found in the glial cells of the peripheral
and central nervous system [4]. As these brain metabolites
typically rise in blood under conditions of neurodegener-
ation [5,6], these results also indicate that a lack of sleep
may be harmful for the brain. Finally, in a cross-sectional
study of 70 adults (mean age 76 years, range 53–91 years)
from the neuroimaging substudy of the Baltimore Longi-
tudinal Study of Aging, it has been shown that self-
reported shorter sleep duration was associated withimer’s Association. This is an open access article under the CC BY-NC-ND
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gregation of Ab in the brain is hypothesized to be linked
to neurodegenerative processes, most notably in Alz-
heimer disease (AD) [8].
Against this background, the present study, involving
1574 men at age 50 years with a mean follow-up of
w40 years, aimed to ascertain if reports of sleep distur-
bances were associated with an increased risk to develop
all-cause dementia. In addition, we examined if reports of
sleep disturbances were linked to changes in plasma levels
of Ab peptides 1–40 and 1–42.2. Methods
2.1. Patient population
The Uppsala Longitudinal Study of Adult Men (ULSAM)
was initiated in 1970. All 50-year-oldmen born between 1920Fig. 1. Flowchart: Uppsala Longitudinal Study of Adult Men (ULSAM). NCI, no
are insufficient and allows no further classification.and 1924 and living in Uppsala, Sweden, were invited to
participate in a health survey aimed at identifying cardiovas-
cular risk factors ([9]; see also http://www.pubcare.uu.se/
ULSAM). Of the 2841 invited men, 82% (2322 men) partici-
pated in the investigation. Following the baseline investigation
at age 50 years, subjects were re-examined at ages 60, 70, 77,
82, and 88 years. To examine the associations of self-reported
sleep disturbanceswith all-cause dementia risk, a total of 1574
participants who had available follow-up data were entered
into the present analysis (w68% of the men who participated
in the baseline investigation; Fig. 1). In a subsample of those
1574 men, plasma levels of Ab peptides 1–40 and 1–42
were determined at ages 70, 77, and 82 years (Fig. 1). These
data were used to ascertain the association between plasma
levels of Ab peptides 1–40, 1–42, and their ratio, with self-
reported sleep disturbance at age 70 years. All participants
gave their informed consent and the Ethics Committee of
Uppsala University approved the study.t cognitively intact, which means evidence of cognitive impairment but data
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At ages 50 and 70 years, participants were administered
three sleep-related questions which could be answered either
“no” or “yes”: Do you have difficulties falling asleep at
night?, Do you often wake up in the early hours, unable to
get back to sleep?, and Do you take sleeping pills more
than 3 times per week?. Answering “yes” to any of the three
questions was herein considered to demonstrate that the
participant at the time of the survey was likely to have a sleep
disturbance. Thus, the three questions were combined into
one variable (denoted “sleep disturbance”), which was given
the value of 1 (present) if any of the three questions were
answered as “yes” (i.e. a score of 1–3) and 0 (absent) other-
wise (score 0). No established standardized questionnaires
about sleep disturbances were available at the time of the
baseline examination.2.3. Primary outcome variable
The primary end point was the diagnosis of dementia.
Dementia was assessed as described earlier [10]. Briefly,
the medical records of the ULSAM participants from all
the clinics of Uppsala University Hospital, the Uppsala
general practitioners and nursing homes, were reviewed
until January 1, 2010. Practically all medical care for the
participants had been provided in these settings. The diag-
noses of dementia were assigned by two experienced geri-
atricians independently, blinded from the baseline data,
using all available data from these records. In the case of
disagreement, a third experienced geriatrician reviewed
the case and the diagnosis was determined by majority de-
cision. Dementia was diagnosed according to the criteria
from Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition (DSM-IV) [11]. A poststroke status
with major motor sequelae and/or aphasia precluding neu-
ropsychological testing and/or inferring a major impact on
daily functions (stable over time) was not classified as de-
mentia. AD was diagnosed according to the National Insti-
tute of Neurological and Communicative Diseases and
Stroke and the Alzheimer’s disease and Related Disorders
Association criteria [12]. A detailed description of cogni-
tive decline over time (excluding deterioration in connec-
tion with possible brain ischemia) and relevant cognitive
testing were mandatory prerequisites for a diagnosis of
pure AD. In addition, magnetic resonance imaging or
computed tomography scanning showing either a normal
picture or atrophy, no more than one clinically silent infarc-
tion, and no more than mild white matter lesion were
required for a diagnosis of pure AD. Vascular dementia
was diagnosed according to the Alzheimer’s Disease Diag-
nostic and Treatment Center (ADDTC) core criteria [13],
frontotemporal dementia according to the McKhann
criteria [14] and Lewy body dementia according to the
McKeith criteria [15]. A diagnosis of mixed dementia
was made when both AD and cerebrovascular diseasewere considered to contribute to dementia. Cases of de-
mentia without neuroimaging and without sufficient clin-
ical details in the medical records to set a specific
dementia subtype diagnosis were classified as unspecified
dementia.
2.4. Laboratory assessment
We analyzed Ab 1–40 and Ab 1–42 levels in plasma us-
ing a well-characterized enzyme-linked immunosorbent
assay method with BNT77 (IgA mouse anti-Ab11-28;
Takeda, Osaka, Japan) and horseradish peroxidase-
conjugated detector antibodies (BA27, IgG2 mouse anti-
Ab40; and BC05, IgG1 mouse anti-Ab42; Takeda), as
previously described [16]. We analyzed Ab40 in duplicate
and Ab42 in triplicate samples.
2.5. Covariates
Body mass index (BMI) was calculated as weight (in kg)
divided by height (in m) squared (kg/m2). The presence of
elevated blood pressure was defined as systolic blood pres-
sure 140 mm Hg and/or diastolic blood pressure 90 mm
Hg, and/or use of antihypertensive medication. The presence
of diabeteswas defined as fasting blood glucose6.1mmol/l
and/or use of oral hypoglycemic agents or insulin. Leisure-
time physical activity was assessed as previously described
[17]. Briefly, the following questions were administered to
the participants: Do you spend most of your time with
reading, watching television, going to the cinema, or
engaging in other, mostly?, Do you often go walking or
cycling for pleasure?, Do you engage in any active recrea-
tional sports or heavy gardening for at least 3 hours every
week?, andDo you regularly engage in hard physical training
or competitive sport?. The highest positive physical activity
response level was used for each participant. Education level
was stratified as low (elementary school), medium (high
school), or high (college studies or higher).
2.6. Statistical analysis
To explore the association between self-reported sleep
disturbance and dementia, a cox regression analysis was
chosen. The Cox regression analysis used time-updated
exposure and covariate information (i.e. the variables
were measured at ages 50 and 70). Time at risk was calcu-
lated from exact age to the age of dementia diagnosis,
death, or age at end of follow-up ( January 1, 2010), which-
ever came first. Dates of death were obtained from the
continuously updated cause of death register held by the
National Board of Health and Welfare in Sweden. The as-
sociations of self-reported sleep disturbance (categorical
variable) with dementia were investigated using three
multivariable models. Model A was adjusted for exact
age (continuous variable), model B for lifestyle factors
(Model A1 body mass index (continuous variable),
leisure-time physical activity (categorical variable) and
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cardiometabolic risk factors (Model B1 hypertension (cat-
egorical variable) and diabetes (categorical variable)). Pro-
portional hazards assumptions were confirmed using
graphical evaluation. A linear mixed model was used to
analyze the associations between plasma levels of Ab pep-
tides 1–40, 1–42, and their ratio with sleep disturbance at
age 70 years. A two-sided P-value of less than .05 was re-
garded as statistically significant in all analyses. For all an-
alyses, SPSS statistical software package was used (version
20.0; SPSS, Inc., Chicago, IL, USA).3. Results
3.1. Descriptive
Characteristics, stratified by self-reported sleep distur-
bance at ages 50 and 70 years, are shown in Table 1. At
age 50 years, men with self-reported sleep disturbance
were more often diagnosed with hypertension (or received
an antihypertensive treatment) and diabetes (or received an
antidiabetic treatment) than men without self-reported sleep
disturbances (hypertension: c25 5.96, df5 1, P5 .01; dia-
betes: c25 4.83, df5 1,P5 .03). Compared with men in the
group “No Sleep Disturbance”, those who had a sleep distur-
bance at age 50 years reported to be less physically active
during leisure time (c2 5 15.24, df 5 3, P 5 .002). At age
70 years, it was observed that the BMI of men with a sleep
disturbance at age 70 years slightly exceeded that of menTable 1
Characteristics, stratified by self-reported sleep disturbance at ages 50 and
70 years, among participants in the Uppsala Longitudinal Study of Adult
Men (ULSAM)
Characteristic
Age 50 Age 70
Sleep
disturbance
No sleep
disturbance
Sleep
disturbance
No sleep
disturbance
Persons at risk, n 342 1232 236 793
Age, yr, mean (SD) 49.6 (0.6) 49.6 (0.6) 71.0 (.6) 71.0 (.5)
BMI, kg/m2,
mean (SD)
25.0 (3.1) 25.1 (3.2) 26.7 (3.9) 26.1 (3.2)
Leisure-time PA, n (%)
Sedentary 59 (17) 163 (13) 11 (5) 31 (4)
Moderate 136 (40) 431 (35) 93 (39) 264 (33)
Regular 123 (36) 581 (47) 124 (53) 452 (57)
Athletic 24 (7) 57 (5) 8 (3) 46 (6)
Educational
level, n (%)
Primary school 206 (60) 778 (63) 133 (56) 447 (56)
Secondary school 90 (26) 321 (26) 60 (25) 233 (29)
University 46 (13) 133 (11) 43 (18) 113 (14)
Diabetes, n (%)
Yes 9 (3) 13 (1) 38 (16) 99 (12)
No 333 (97) 1219 (99) 198 (84) 694 (88)
Hypertension, n (%)
Yes 84 (25) 229 (19) 85 (36) 240 (30)
No 258 (75) 1003 (81) 151 (64) 553 (70)
Abbreviations: SD, standard deviation; BMI, body mass index; PA, phys-
ical activity.without sleep disturbance (t 5 22.70, df 5 1027,
P 5 .007, independent Students’ t test).
3.2. Self-reported sleep disturbance and dementia risk
In total, the investigated cohort was totally 35.380 years
at risk. Multivariate Cox regression analysis using time-
updated exposure and covariate information demonstrated
that men with self-reported sleep disturbances had a
w1.33-times higher risk to develop all-cause dementia dur-
ing the 40-year observation period when compared with men
without self-reported sleep disturbances (Table 2). This as-
sociation was most pronounced for AD (151%; Table 2).
No significant interactions of the primary effector variable
self-reported sleep disturbance with the covariates educa-
tion, BMI, diabetes, hypertension, leisure-time physical ac-
tivity were obtained by the Cox regression analysis (P  .17
for all interaction terms).
A univariate binary logistic regression was then used to
explore whether the degree of self-reported sleep distur-
bances (i.e. either no self-reported sleep disturbance at all
(69% of the cohort), self-reported sleep disturbance only at
age 50 (16%), self-reported sleep disturbance only at age
70 (9%), or self-reported sleep disturbance at both ages
(6%)) would predict the risk for all-cause dementia. This
analysis revealed that men with self-reported sleep distur-
bances at age 70 years exhibited the highest risk to develop
all-cause dementia (odds ratio [OR] [95% confidence inter-
val (CI)]; 2.14 [1.42,3.21], P , .001), compared with men
without sleep disturbances. In contrast, those who reported
a sleep disturbance at age 50 years did not have a higher
risk to develop all-cause dementia than those without sleep
disturbances (OR [95%CI]; 0.84 [0.56,1.26], P 5 .39).
Similar results were found for the relative risk to develop
AD (OR [95%CI]; men with self-reported sleep disturbance
at age 70 years: 2.92 [1.76,4.87], P , .001; men with self-
reported sleep disturbance at age 50: 0.98 [0.42,2.33],
P 5 .98). Self-reported sleep disturbances at both ages did
not explain additional variance of the observed associations.
3.3. Plasma levels of Ab peptides 40, 42, and their ratio
Utilizing a linear mixed model that was controlled for po-
tential confounders at age 70 years (i.e. physical activity,
educational level, BMI, diabetes state, and hypertension
state), no significant differences were found between reports
of sleep disturbance at age 70 years and plasma levels of Ab
peptides 1–40/1–42 measured at ages 70, 77, and 82 years
(P .11 for all sleep main effects and sleep*time interaction
effects; Fig. 2).4. Discussion
We demonstrate that reports of sleep disturbances were
associated with an increased risk to develop all-cause
dementia in initially cognitively healthy men during a
40-year observation period. Of note, this association was
Table 2
Association between self-reported sleep disturbances and dementia risk in the Uppsala Longitudinal Study of Adult Men (ULSAM)
Characteristic Sleep disturbance No sleep disturbance Model HR (95% CI) P
Persons at risk
Age 50 342 1232 – – –
Age 70 236 793 – – –
All-cause dementia, n (%) baseline) 72 (21) 198 (16) A 1.33 (1.01–1.74) .04
-“- -“- B 1.34 (1.02–1.76) .03
-“- -“- C 1.33 (1.01–1.75) .04
AD, n (% of all-cause dementia) 34 (47) 85 (43) A 1.44 (0.97–2.14) .07
-“- -“- B 1.51 (1.01–2.25) ,.05
-“- -“- C 1.51 (1.01–2.25) ,.05
VaD, n (% of all-cause dementia) 16 (22) 45 (23) A 1.30 (0.73–2.30) .37
-“- -“- B 1.26 (0.71–2.24) .44
-“- -“- C 1.23 (0.69–2.20) .48
AD–VaD, n (% of all-cause dementia) 4 (6) 9 (5) A 1.62 (0.50–5.28) .42
-“- -“- B 1.64 (0.50–5.34) .41
-“- -“- C 1.78 (0.54–5.86) .35
FTD, n (% of all-cause dementia) 2 (3) 4 (2) A 1.87 (0.34–10.23) .47
-“- -“- B 1.75 (0.32–9.67) .52
-“- -“- C 1.76 (0.32–9.82) .52
PDD/LBD, n (% of all-cause dementia) 3 (4) 11 (6) A 1.01 (0.28–3.63) .99
-“- -“- B 0.88 (0.24–3.25) .85
-“- -“- C 0.85 (0.23–3.16) .81
UND, n (% of all-cause dementia) 13 (18) 44 (22) A 1.09 (0.59–2.03) .78
-“- -“- B 1.14 (0.61–2.13) .68
-“- -“- C 1.13 (0.60–2.10) .71
Abbreviations: HR, hazard ratio; CI, confidence interval; cont., continuous; cat., categorical; AD, Alzheimer’s disease; VaD, vascular dementia; FTD, fron-
totemporal dementia; PDD/LBD, Lewy body dementia; UND, unspecified dementia.
NOTE. Time at risk was calculated from exact age at first examination to the date of dementia diagnosis, death, or end of follow-up, whichever came first. The
Cox regression analysis used time-updated exposure and covariate information.
Bold values indicate statistical significance (ie: P , 0.05).
Model A indicates model adjusted for age.
Model B indicates lifestyle model (age, body mass index [cont.], leisure-time physical activity [cat.], and educational level [cat.]).
Model C was additionally adjusted for cardiometabolic factors (Model B 1 hypertension [cat.] and diabetes [cat.]).
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1–40 and 1–42 were not different between those who re-
ported to have a sleep disturbance and those who did not.
These community-based data confirm and extend previous
experimental and epidemiological research [1,2,18–20]
that suggest that getting a regular good night’s sleep may
be a useful means for supporting long-term brain health in
humans.4.1. Comparison with literature
A recent longitudinal study using data from a population-
based sample of 214 Swedish adults aged 75 years and over
demonstrated that reduced sleep duration was associated
with a 75% increased all-cause dementia risk and double
the risk of AD [20]. Similar but weaker associations were
observed in the present study. That the strength of our asso-
ciation is less pronounced than that observed in the prior
study by Hahn et al. may be explained by differences in
the sample size (ours vs. Hahn’s study: 1606 vs. 214), gender
distribution (100% males vs. 80%/20% females/males),
length of observation period (40 years vs. 9 years), the num-
ber of sleep disturbance assessments (baseline and age 70
years vs. baseline), clinical characteristics of the study sam-ples, and age at entry (50 years vs. 83 years). Supporting the
view that especially age may modulate the strength of the as-
sociation between sleep disturbances and dementia risk, we
found that men with self-reported sleep disturbances at age
70 years but not 50 years had a twofold higher risk to develop
dementia and a threefold higher risk to develop AD, than
those without any sleep disturbance. A possible explanation
could be that the ability of the aged brain to clean itself from
neurotoxic substances during sleep might be more attenu-
ated than at a younger age when sleep is disturbed.
Another finding of our study is that reported sleep distur-
bance at age 70 years was neither linked to plasma levels of
Ab peptides 1–40 and 1–42 measured at the same age, nor at
a later time point. At first glance, these results contrast pre-
vious findings. For instance, by analyzing CSF from 145
cognitively normal individuals who were 45 years and older,
researchers were able to demonstrate that CSF Ab 1–42
levels were lower in those who have objectively (i.e.
measured by wrist actigraphy) lower sleep quality [19].
Moreover, as mentioned earlier, self-reported shorter sleep
duration has been associated with greater Ab burden in the
brain of 70 elderly subjects [7]. Several reasons may have
masked possible effects on Ab peptides 1–40 and 1–42.
First, plasma may be less sensitive than CSF to reflect a
Fig. 2. No significant differences in plasma amyloid beta peptides (measured
at ages 70, 77, and 82 years) between men with and without self-
reported sleep disturbance at age 70 years. Data are mean 6 standard
deviation.
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tides. Second, plasma levels of Ab peptides were measured
at ages 70, 77, and 82 years. Bearing in mind that plasma Ab
peptides usually increase before the onset of dementia but
decrease thereafter [21], we cannot rule out that the chosen
blood sampling frequency may not have captured possible
differences in plasma levels of Ab peptides 1–40 and 1–42
between the groups with and without reported sleep distur-
bances. Finally, it must be noted that the use of plasma Ab
peptides 1–40 and 1–42 to predict reliably the transition of
cognitive decline to AD is subject of ongoing scientific
debate [22,23].
4.2. Potential mechanisms for the observed associations
Our observational study is limited as we cannot yet estab-
lish causality. There are several potential pathways that may
explain the association between reports of sleep disturbance
and the risk to develop all-cause dementia and AD, respec-
tively. Sleep represents a period during which brain glucose
metabolism drops by w30%, compared with values ob-
tained during wakefulness [24]. Substrate oxidation ulti-
mately leads to the production of reactive oxygen species
(ROS), such as hydrogen peroxide [25]. Previous experi-
ments have demonstrated that ROS can damage neurons
and even induce cell death [26]. Another possible interpreta-
tion could be, as described earlier, that poor sleep may lessen
the ability of the brain to remove toxic substances [1],
thereby increasing and prolonging the exposure of neurons
to neurodegenerative factors, ultimately perhaps resulting
in reversible or irreversible neuronal damage, depending
on the length and degree of exposure to sleep deprivation.
However, it is important to note that, as of yet, evidence islacking that perceived lower-quality sleep may concur
with a greater neurodegenerative load and/or a reduced abil-
ity of the brain to clear itself from toxic substances.
Importantly, it must be borne in mind that self-reported
sleep disturbances, unlike a nocturnal polysomnography
(NSPG), do not allow one to draw firm conclusions as to
whether an individual’s sleep architecture is healthy or not.
Thus, it cannot be ruled out that self-reported sleep distur-
bances in our study were related to age-related changes in
sleep patterns, poor sleep hygiene, and/or environmental sleep
issues. In addition, self-reported sleep disturbances may be
secondary to a primary disease (e.g. depression), which by it-
self increases the risk for neurodegenerative processes.
Finally, menwith sleep disturbances hadmore often hyperten-
sion, diabetes, and a higher BMI than men without sleep dis-
turbances. Similar medical conditions are found in patients
with sleep apnea [27–29]. Interestingly, this sleep disorder
has recently been linked to neurodegenerative processes [30].4.3. Strengths and limitations
The major strength of our investigation includes the long
follow-up period (w40 years). During aging, total sleep
time, sleep efficiency, percentage of slow-wave sleep, percent-
age of rapid eye movement sleep, and rapid eye movement
sleep latency all significantly decrease [31], indicating that
repeated measures of sleep disturbance—as collected in the
present study—help minimize the confounding effect of age
on sleep quality. However, there are also several limitations
that apply: A history of chronic insomnia does not per se pre-
dict poor sleep as determined by NSPG [32]. That said, our
findings must be confirmed by prospective studies utilizing
objective measures of sleep quality (e.g. actigraphy, NSPG).
Nevertheless, the consistency of the association between re-
ports of sleep disturbance and risk to develop dementia would
argue against the results as chance findings. Moreover, it must
be borne inmind thatmedical conditions that were not entered
in the present analysis as possible confounders can adversely
impact human sleep architecture (e.g. depression, e.g. as found
by Hahn et al. [20]), and may therefore partly account for the
observed association between sleep disturbance and dementia
risk. Another limitation is the unknown generalizability to fe-
males and other geographical and ethnic groups. Finally, con-
founds by other factors, such as genetic background (e.g.
apolipoproteinE [33];), thatwere not considered in the present
analysis, cannot be excluded.5. Conclusion
Approximately every other adult in North America re-
ports the quality of their nighttime sleep as being insufficient
[34]. Furthermore, insomnia and decreased sleep quality are
typical attending ills of many widespread diseases in modern
societies (e.g. diabetes, hypertension, and obesity) [35–38].
Thus, in our view our findings are relevant for both the public
and healthcare practitioners, as they suggest that strategies
C. Benedict et al. / Alzheimer’s & Dementia 11 (2015) 1090-10971096aimed at improving sleep quality (e.g. regular exercise) may
help reduce the neurodegenerative risk for a significant
proportion of our society.
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1. Systematic review: We searched reports from cohort
studies to identify studies reporting on the epidemi-
ology of sleep disturbances and dementia risk.
Except for several cross-sectional studies (e.g.
involving neuroimaging techniques), no longitudinal
study with a follow-up period that was similar to ours
(i.e. 40 years) was identified.
2. Interpretation: We demonstrate that reports of sleep
disturbances were associated with an increased risk
to develop all-cause dementia and Alzheimer’s dis-
ease in initially cognitively healthy men during a 40-
year observation period. These findings could be
relevant for both the public and healthcare practi-
tioners, as they suggest that strategies aimed at
improving sleep quality (e.g. exercise) may help
reduce the neurodegenerative risk of elderly men.
3. Future directions: Studies utilizing methods that
objectively measure sleep (e.g. nocturnal polysom-
nography) will help to further our understanding as
to why poor sleep patterns increases our risk to
develop neurodegenerative diseases. In this context,
interventional studies with the intention of improving
sleep patterns will be necessary to test whether such
interventions can reduce the risk of developing
neurodegenerative diseases and thus perhaps main-
tain cognitive health into older age.References
[1] Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep
drives metabolite clearance from the adult brain. Science 2013;
342:373–7.
[2] Benedict C, Cedernaes J, Giedraitis V, Nillson EK, Hogenkamp PS,
Vagesj€o E, et al. Acute sleep deprivation increases serum levels ofneuron-specific enolase (NSE) and S100 calcium binding protein B
(S-100B) in healthy young men. Sleep 2014;37:195–8.
[3] Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically
useful marker for neurons and neuroendocrine cells. Annu Rev Neuro-
sci 1987;10:269–95.
[4] Olsson B, Zetterberg H, Hampel H, Blennow K. Biomarker-based
dissection of neurodegenerative diseases. Prog Neurobiol 2011;
95:520–34.
[5] Schattling B, Steinbach K, Thies E, KruseM,Menigoz A, Ufer F, et al.
TRPM4 cation channel mediates axonal and neuronal degeneration in
experimental autoimmune encephalomyelitis and multiple sclerosis.
Nat Med 2012;18:1805–11.
[6] Steiner J, Bogerts B, Schroeter ML, Bernstein HG. S100B protein in
neurodegenerative disorders. Clin Chem Lab Med 2011;49:409–24.
[7] Spira AP, GamaldoAA, AnY,WuMN, Simonsick EM, BilgelM, et al.
Self-reported sleep and b-amyloid deposition in community-dwelling
older adults. JAMA Neurol 2013;70:1537–43.
[8] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 2002;
297:353–6.
[9] Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R,
Lithell H. Plasminogen activator inhibitor-1 activity is independently
related to both insulin sensitivity and serum triglycerides in 70-year-
old men. Arterioscler Thromb Vasc Biol 1998;18:258–64.
[10] R€onnemaa E, Zethelius B, Lannfelt L, Kilander L. Vascular risk fac-
tors and dementia: 40-year follow-up of a population-based cohort.
Dement Geriatr Cogn Disord 2011;31:460–6.
[11] APA. Diagnostic and statistical manual of mental disorders: DSM IV.
Washington: APA; 1994.
[12] McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the
NINCDS-ADRDA work group under the auspices of Department of
Health and Human Services Task Force on Alzheimer’s Disease.
Neurology 1984;34:939–44.
[13] Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R.
Criteria for the diagnosis of ischemic vascular dementia proposed by
the State of California Alzheimer’s Disease Diagnostic and Treatment
Centers. Neurology 1992;42:473–80.
[14] McKhann GM, Albert MS, Grossman M, Miller B, Dickson D,
Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal
dementia: report of the Work Group on Frontotemporal Dementia and
Pick’s Disease. Arch Neurol 2001;58:1803–9.
[15] McKeith IG. Consensus guidelines for the clinical and pathologic diag-
nosis of dementiawith lewy bodies (DLB): report of the Consortium on
DLB International Workshop. J Alzheimers Dis 2006;9:417–23.
[16] Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH,
IrizarryMC. Age but not diagnosis is the main predictor of plasma am-
yloid beta-protein levels. Arch Neurol 2003;60:958–64.
[17] Byberg L, Zethelius B, McKeigue PM, Lithell HO. Changes in phys-
ical activity are associated with changes in metabolic cardiovascular
risk factors. Diabetologia 2001;44:2134–9.
[18] Osorio RS, Pirraglia E, Ag€uera-Ortiz LF, During EH, Sacks H,
Ayappa I, et al. Greater risk of Alzheimer’s disease in older adults
with insomnia. J Am Geriatr Soc 2011;59:559–62.
[19] Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM,
Duntley SP, et al. Sleep quality and preclinical Alzheimer disease.
JAMA Neurol 2013;70:587–93.
[20] Hahn EA, Wang HX, Andel R, Fratiglioni L. A change in sleep pattern
may predict Alzheimer disease. Am J Geriatr Psychiatry 2013; http://
dx.doi.org/10.1016/j.jagp.2013.04.015. pii: S1064-7481(13)00233-9.
[21] Henry MS, Passmore AP, Todd S, McGuinness B, Craig D,
Johnston JA. The development of effective biomarkers for Alzheimer’s
disease: a review. Int J Geriatr Psychiatry 2013;28:331–40.
[22] Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL,
Trounson BO, et al., AIBL research group. Changes in plasma amyloid
beta in a longitudinal study of aging and Alzheimer’s disease. Alz-
heimers Dement 2014;10:53–61.
C. Benedict et al. / Alzheimer’s & Dementia 11 (2015) 1090-1097 1097[23] Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measure-
ments – a desired but elusive Alzheimer’s disease biomarker. Alz-
heimers Res Ther 2013;5:8.
[24] Boyle PJ, Scott JC, Krentz AJ, Nagy RJ, Comstock E, Hoffman C.
Diminished brain glucose metabolism is a significant determinant
for falling rates of systemic glucose utilization during sleep in normal
humans. J Clin Invest 1994;93:529–35.
[25] McCord JM. Human disease, free radicals, and the oxidant/antioxidant
balance. Clin Biochem 1993;26:351–7.
[26] Fukui K, Takatsu H, Koike T, Urano S. Hydrogen peroxide induces
neurite degeneration: prevention by tocotrienols. Free Radic Res
2011;45:681–91.
[27] Konecny T, Kara T, Somers VK. Obstructive sleep apnea and hyper-
tension: an update. Hypertension 2014;63:203–9.
[28] Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interac-
tions between obesity and obstructive sleep apnea: implications for
treatment. Chest 2010;137:711–9.
[29] Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and type
2 diabetes: interacting epidemics. Chest 2008;133:496–506.
[30] Osorio RS, Ayappa I, Mantua J, Gumb T, Varga A, Mooney AM, et al.
The interaction between sleep-disordered breathing and apolipopro-
tein E genotype on cerebrospinal fluid biomarkers for Alzheimer’s dis-
ease in cognitively normal elderly individuals. Neurobiol Aging 2014;
35:1318–24.
[31] Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-
analysis of quantitative sleep parameters from childhood to old agein healthy individuals: developing normative sleep values across the
human lifespan. Sleep 2004;27:1255–73.
[32] Rosa RR, Bonnet MH. Reported chronic insomnia is independent of
poor sleep as measured by electroencephalography. Psychosom Med
2000;62:474–82.
[33] Lim AS, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA.
Modification of the relationship of the apolipoprotein e ε4 allele to the
risk of Alzheimer disease and neurofibrillary tangle density by sleep.
JAMA Neurol 2013;70:1544–51.
[34] The National Sleep Foundation. 2013 International Bedroom Poll.
Available at: http://www.sleepfoundation.org/article/press-release/
national-sleep-foundation-2013-international-bedroom-poll. Accessed
December 19, 2013.
[35] Jauch-Chara K, Schmid SM, Hallschmid M, Born J, Schultes B.
Altered neuroendocrine sleep architecture in patients with type 1 dia-
betes. Diabetes Care 2008;31:1183–8.
[36] Mokhlesi B, Pannain S, Ghods F, Knutson KL. Predictors of slow-
wave sleep in a clinic-based sample. J Sleep Res 2012;21:170–5.
[37] Fung MM, Peters K, Redline S, Ziegler MG, Ancoli-Israel S, Barrett-
Connor E, et al. Osteoporotic Fractures in Men Research Group.
Decreased slow wave sleep increases risk of developing hypertension
in elderly men. Hypertension 2011;58:596–603.
[38] Kline CE, Irish LA, Krafty RT, Sternfeld B, Kravitz HM, Buysse DJ,
et al. Consistently high sports/exercise activity is associated with bet-
ter sleep quality, continuity and depth in midlife women: the SWAN
sleep study. Sleep 2013;36:1279–88.
